A combination vaccine comprising i) inactivated polio virus antigen selected from Salk or Sabin strain; ii) inactivated rotavirus antigen; wherein said inactivated polio virus antigen is a dose reduced inactivated polio virus antigen selected from a group comprising of i) dose composition having Sabin Type 1, Type 2, Type 3 combination selected from 5-16-10 D-antigen units, ii) dose composition having Sabin Type 1, Type 2, Type 3 combination selected from 2.5-8-5 D-antigen units, iii) dose composition having Sabin Type 1, Type 2, Type 3 combination selected from 5-8-10 D-antigen units, iv) dose composition having Salk Type 1, Type 2, Type 3 combination selected from 7.5-16-10 D-antigen units, v) dose composition having Salk Type 1, Type 2, Type 3 combination selected from 8-2-5 D-antigen units, vi) dose composition having Salk Type 1, Type 2, Type 3 combination selected from 10-2-5 D-antigen units, vii) dose composition having Salk Type 1, Type 2, Type 3 combination selected from 10-2-10 D-antigen units, viii) dose composition having Salk Type 1, Type 2, Type 3 combination selected from 10-2-12 D-antigen units, ix) dose composition having Salk Type 1, Type 2, Type 3 combination selected from 10-2-16 D-antigen units, x) dose composition having Salk Type 1, Type 2, Type 3 combination selected from 7.5-16-10 D-antigen units, xi) dose composition having Salk Type 1, Type 2, Type 3 combination selected from 5-2-5 D-antigen units, wherein said dose reduced inactivated polio virus antigen is adsorbed on aluminium hydroxide adjuvant, wherein percent adsorption of aluminium hydroxide is in the range of 70-99%, wherein the rotavirus antigen is heat inactivated CDC-9 rotavirus strain and is adsorbed on aluminium hydroxide adjuvant, and wherein the concentration of rotavirus antigen is 10 μg/dose. i) inactivated polio virus antigen selected from Salk or Sabin strain; ii) inactivated rotavirus antigen; wherein said inactivated polio virus antigen is a dose reduced inactivated polio virus antigen selected from a group comprising of i) dose composition having Sabin Type 1, Type 2, Type 3 combination selected from 5-16-10 D-antigen units, ii) dose composition having Sabin Type 1, Type 2, Type 3 combination selected from 2.5-8-5 D-antigen units, iii) dose composition having Sabin Type 1, Type 2, Type 3 combination selected from 5-8-10 D-antigen units, iv) dose composition having Salk Type 1, Type 2, Type 3 combination selected from 7.5-16-10 D-antigen units, v) dose composition having Salk Type 1, Type 2, Type 3 combination selected from 8-2-5 D-antigen units, vi) dose composition having Salk Type 1, Type 2, Type 3 combination selected from 10-2-5 D-antigen units, vii) dose composition having Salk Type 1, Type 2, Type 3 combination selected from 10-2-10 D-antigen units, viii) dose composition having Salk Type 1, Type 2, Type 3 combination selected from 10-2-12 D-antigen units, ix) dose composition having Salk Type 1, Type 2, Type 3 combination selected from 10-2-16 D-antigen units, x) dose composition having Salk Type 1, Type 2, Type 3 combination selected from 7.5-16-10 D-antigen units, xi) dose composition having Salk Type 1, Type 2, Type 3 combination selected from 5-2-5 D-antigen units, i) dose composition having Sabin Type 1, Type 2, Type 3 combination selected from 5-16-10 D-antigen units, ii) dose composition having Sabin Type 1, Type 2, Type 3 combination selected from 2.5-8-5 D-antigen units, iii) dose composition having Sabin Type 1, Type 2, Type 3 combination selected from 5-8-10 D-antigen units, iv) dose composition having Salk Type 1, Type 2, Type 3 combination selected from 7.5-16-10 D-antigen units, v) dose composition having Salk Type 1, Type 2, Type 3 combination selected from 8-2-5 D-antigen units, vi) dose composition having Salk Type 1, Type 2, Type 3 combination selected from 10-2-5 D-antigen units, vii) dose composition having Salk Type 1, Type 2, Type 3 combination selected from 10-2-10 D-antigen units, viii) dose composition having Salk Type 1, Type 2, Type 3 combination selected from 10-2-12 D-antigen units, ix) dose composition having Salk Type 1, Type 2, Type 3 combination selected from 10-2-16 D-antigen units, x) dose composition having Salk Type 1, Type 2, Type 3 combination selected from 7.5-16-10 D-antigen units, xi) dose composition having Salk Type 1, Type 2, Type 3 combination selected from 5-2-5 D-antigen units, wherein said dose reduced inactivated polio virus antigen is adsorbed on aluminium hydroxide adjuvant, wherein percent adsorption of aluminium hydroxide is in the range of 70-99%, wherein the rotavirus antigen is heat inactivated CDC-9 rotavirus strain and is adsorbed on aluminium hydroxide adjuvant, and wherein the concentration of rotavirus antigen is 10 μg/dose.